Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | STS | P08842 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377756 | 0.87 | CNR2 (0.61) | CNR2PKMSTSKMT2AMEN1 | |
| SCHEMBL2638023 | 0.86 | CNR2 (0.47) | CNR2PKMSTSKMT2AMEN1 | |
| SCHEMBL2638344 | 0.85 | CNR2 (0.79) | CNR2PKMSTSKMT2AMEN1 | |
| SCHEMBL2638038 | 0.84 | STS (0.49) | CNR2PKMSTSKMT2AFAAH | |
| SCHEMBL2638431 | 0.82 | CNR2 (0.70) | CNR2PKMKMT2AMEN1FAAH | |
| SCHEMBL2638614 | 0.81 | POLB (0.53) | CNR2PKMSTSFAAHHSD11B1 | |
| SCHEMBL2638886 | 0.81 | FAAH (0.73) | CNR2PKMKMT2AMEN1FAAH | |
| SCHEMBL2638487 | 0.79 | GRM5 (0.53) | CNR2PKMSTSKMT2AMEN1 | |
| SCHEMBL3374035 | 0.79 | CNR2 (0.57) | CNR2PKMKMT2AMEN1FAAH | |
| SCHEMBL3376407 | 0.79 | CNR2 (0.50) | CNR2PKMKMT2AMEN1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | claimed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| US-8716284-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | disclosed |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-07-18 | — | — | US | disclosed |
| US-8389519-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2013-03-05 | — | — | US | disclosed |
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-10-25 | — | — | US | disclosed |
| US-8198275-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | CNR2 1628/4885PKM 3876/4885STS 1706/4885 |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | CNR2 1603/4885PKM 4088/4885STS 1968/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | CNR2 1681/4885PKM 3889/4885STS 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.